ROCKVILLE, Md.--(BUSINESS WIRE)--Meso Scale Discovery, a division of Meso Scale Diagnostics, LLC. (MSD), today launched V-PLEX® immunoassays validated for the detection of the biomarkers IL-17A, IL-21, IL-22, IL-23, IL-27, and MIP-3α in human cell culture supernatants, serum, plasma, and urine.
As part of several major T-cell-related pathways, these biomarkers are subjects of drug discovery projects, diagnostics development, and basic research.
“These new analytes are of tremendous interest to researchers studying a variety of immune and autoimmune disorders,” said Jacob Wohlstadter, president and chief executive officer of MSD. “We are excited to make them available to the scientific community as validated V-PLEX assays.”
Th17 cells are a critical part of the immune system and act as a bridge between the innate and adaptive immune systems. Improper regulation of their proinflammatory activities contributes to numerous pathogenic conditions such as type 1 diabetes, Crohn’s disease, lupus, multiple sclerosis, and rheumatoid arthritis.
James Wilbur, Ph.D., general manager of MSD, noted, “Our validated V-PLEX immunoassay platform was developed specifically for applications where long-term studies drive crucial decisions, and only the highest quality data will suffice. These assays represent our longstanding commitment to serving our customers.”
V-PLEX assays support research ranging from screening and discovery to drug development. MSD currently offers 46 human V-PLEX assays, developed for researchers studying immunology, inflammation, neurodegeneration, and angiogenic disorders. These assays are based on MSD’s proprietary electrochemiluminescence technology, which delivers up to 6 logs of dynamic range and has been cited in over 1,300 peer-reviewed references.
V-PLEX assays, available as individual validated assays or as part of validated panels, are for Research Use Only and are available for immediate purchase and delivery.
About Meso Scale Diagnostics, LLC.
Meso Scale Diagnostics, LLC., based in Rockville, Maryland, develops, manufactures, and markets instruments and assays for array-based biological measurements for research use in life sciences and for biodefense applications. MSD is the world’s leading provider of highly sensitive multiplex immunoassays. More information about MSD and its products can be found at www.mesoscale.com.